Clifford Chance advises on TenNor Therapeutics' IPO and listing in Hong Kong

Global law firm Clifford Chance has advised the joint sponsors CITIC Securities (Hong Kong) Limited and ABCI Securities Company Limited on the initial public offering and listing of TenNor Therapeutics (Suzhou) Limited on the Main Board of the Hong Kong Stock Exchange, under the Exchange's Chapter 18A Listing Rules for Biotech Companies.

Founded in 2013 in Suzhou, TenNor Therapeutics is a biotechnology company which focuses on developing differentiated treatments for bacterial infections and metabolic diseases to combat antimicrobial resistance, a global health threat.

Partners Fang Liu, Virginia Lee and partner of Clifford Chance (Beijing) Claire Cao co-led the transaction with support from counsel Haoze Zheng, senior associate Astrid Zhuang, associates Cathy Qian and Ke Shi, trainee solicitors Zhongxiao Cong and Ruiyi Chen, legal analysts Bofan Xu, Andy Jiang, Vanessa Xu, paralegal Jay Lee.

Clifford Chance is a leading adviser of pharmaceutical, biotech and healthcare companies, having advised most recently on the listings of Star Sports Medicine, Edge Medical and Lepu Biopharma.